Introduction of Noninvasive Prenatal Testing for Blood Group and Platelet Antigens from Cell-Free Plasma DNA Using Digital PCR.

Blood group genotyping Cell-free DNA Digital PCR Noninvasive prenatal testing

Journal

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie
ISSN: 1660-3796
Titre abrégé: Transfus Med Hemother
Pays: Switzerland
ID NLM: 101176417

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 08 08 2019
accepted: 24 10 2019
entrez: 5 9 2020
pubmed: 5 9 2020
medline: 5 9 2020
Statut: ppublish

Résumé

Noninvasive prenatal testing (NIPT) for fetal antigens is a common standard for targeted immune prophylaxis in RhD-mediated hemolytic disease of the fetus and newborn, and is most frequently done by quantitative PCR (qPCR). A similar approach is considered for other blood group and human platelet alloantigens (HPA). Because of a higher sensitivity compared to qPCR for rare molecule detection, we established and validated digital PCR (dPCR) assays for the detection of Validation was performed on dilution series of mixed plasma samples from volunteer donors with known genotypes. After preamplification of the target loci, two-color (FAM and VIC) TaqMan The Analysis of cfDNA from maternal plasma using dPCR is suitable for the detection of fetal alleles. Because of the high sensitivity of the assays, the NIPT protocol for RhD, KEL1, and HPA can also be applied to earlier stages of pregnancy.

Sections du résumé

BACKGROUND BACKGROUND
Noninvasive prenatal testing (NIPT) for fetal antigens is a common standard for targeted immune prophylaxis in RhD-mediated hemolytic disease of the fetus and newborn, and is most frequently done by quantitative PCR (qPCR). A similar approach is considered for other blood group and human platelet alloantigens (HPA). Because of a higher sensitivity compared to qPCR for rare molecule detection, we established and validated digital PCR (dPCR) assays for the detection of
METHODS METHODS
Validation was performed on dilution series of mixed plasma samples from volunteer donors with known genotypes. After preamplification of the target loci, two-color (FAM and VIC) TaqMan
RESULTS RESULTS
The
CONCLUSION CONCLUSIONS
Analysis of cfDNA from maternal plasma using dPCR is suitable for the detection of fetal alleles. Because of the high sensitivity of the assays, the NIPT protocol for RhD, KEL1, and HPA can also be applied to earlier stages of pregnancy.

Identifiants

pubmed: 32884502
doi: 10.1159/000504348
pii: tmh-0047-0292
pmc: PMC7443669
doi:

Types de publication

Journal Article

Langues

eng

Pagination

292-301

Informations de copyright

Copyright © 2019 by S. Karger AG, Basel.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Lancet. 1993 May 1;341(8853):1147-8
pubmed: 8097823
Semin Fetal Neonatal Med. 2008 Aug;13(4):207-14
pubmed: 18396474
Transfusion. 2015 Jun;55(6 Pt 2):1538-44
pubmed: 25873286
Am J Obstet Gynecol. 2018 Sep;219(3):291.e1-291.e9
pubmed: 29902448
Br J Haematol. 2013 May;161(4):461-70
pubmed: 23432139
Acta Obstet Gynecol Scand. 2017 Oct;96(10):1228-1233
pubmed: 28718198
Br J Haematol. 2017 Oct;179(1):10-19
pubmed: 28508413
BJOG. 2011 Oct;118(11):1340-8
pubmed: 21668766
Transfusion. 2002 Aug;42(8):1079-85
pubmed: 12385421
BJOG. 2011 Oct;118(11):1392-5
pubmed: 21749627
BMC Pregnancy Childbirth. 2014 Feb 25;14:87
pubmed: 24568571
J Immunol Methods. 1982 Mar 12;49(2):R11-23
pubmed: 7040548
Transfusion. 2013 Feb;53(2):353-62
pubmed: 22691192
Transfusion. 2018 Nov;58(11):2705-2711
pubmed: 30260485
Transfusion. 1999 Nov-Dec;39(11-12):1259-65
pubmed: 10604255
Br J Haematol. 1996 Jun;93(3):720-7
pubmed: 8652401
Transfus Med. 2014 Feb;24(1):1-7
pubmed: 25121157
Electrophoresis. 2006 May;27(9):1713-24
pubmed: 16586411
Transfusion. 2008 Nov;48(11):2292-301
pubmed: 18694461
Am J Reprod Immunol. 2016 Dec;76(6):499-503
pubmed: 27730708
Health Technol Assess. 2018 Mar;22(13):1-172
pubmed: 29580376
Transfusion. 2013 Nov;53(11 Suppl 2):2892-8
pubmed: 23550721
PLoS One. 2015 Nov 12;10(11):e0142572
pubmed: 26562517
Vox Sang. 2014 Feb;106(2):93-102
pubmed: 24102564
BMJ. 2016 Nov 7;355:i5789
pubmed: 27821701
Int J Legal Med. 2018 Mar;132(2):343-352
pubmed: 28429088
Biotechniques. 1993 Oct;15(4):636-8, 640-1
pubmed: 8251166
Clin Chem. 2015 Nov;61(11):1399-407
pubmed: 26354802
Prenat Diagn. 2014 Oct;34(10):1000-5
pubmed: 24860987
Exp Ther Med. 2015 Apr;9(4):1383-1388
pubmed: 25780439
Transfusion. 2018 Jul;58(7):1792-1799
pubmed: 29536546
Transfus Med Hemother. 2018 Oct;45(5):331-340
pubmed: 30498411

Auteurs

Marion Eryilmaz (M)

Institute of Transfusion Medicine and Immunology, Heidelberg University, Medical Faculty Mannheim, German Red Cross Blood Service Baden-Württemberg - Hessen, Mannheim, Germany.

Dennis Müller (D)

Institute of Transfusion Medicine and Immunology, Heidelberg University, Medical Faculty Mannheim, German Red Cross Blood Service Baden-Württemberg - Hessen, Mannheim, Germany.

Gabi Rink (G)

Institute of Transfusion Medicine and Immunology, Heidelberg University, Medical Faculty Mannheim, German Red Cross Blood Service Baden-Württemberg - Hessen, Mannheim, Germany.

Harald Klüter (H)

Institute of Transfusion Medicine and Immunology, Heidelberg University, Medical Faculty Mannheim, German Red Cross Blood Service Baden-Württemberg - Hessen, Mannheim, Germany.

Peter Bugert (P)

Institute of Transfusion Medicine and Immunology, Heidelberg University, Medical Faculty Mannheim, German Red Cross Blood Service Baden-Württemberg - Hessen, Mannheim, Germany.

Classifications MeSH